8th INTERNATIONAL MYOLOGY CONGRESS Paris, France | 22 - 25 April 2024
advance I am a healthcare professional registered in the EU I am not a
healthcare professional
Watch Dr Béhin and Prof. Annane talk about the legacy and innovation of myasthenia gravis (MG) treatment and guide us through disease burden, pathophysiology, and role of complement in MG in this Alexion-sponsored symposium at the 8th International Myology Congress held on April 24, 2024, in Paris, France.
img example

Dr Anthony Béhin, MD​

APHP – GH Pitié-Salpêtrière, 
​Institute of Myology,​
Paris, France​

Anthony Béhin is a medical doctor at the Pitié-Salpêtrière University Hospital, part of the APHP Greater Paris University Hospitals, and is affiliated with the reference center for neuromuscular disorders at the Institute of Myology in Paris, France.

Dr Béhin has an expertise in neurology and neuromuscular disorders and has authored more than 200 research publications.

Prof. Djillali Annane, MD

Hôpital Raymond 
Poincaré (APHP, GHU Paris), Garches​ Université de Versailles Saint Quentin, ​
Université Paris Saclay,​ France

Djillali Annane is a professor in medicine at University Paris Saclay and director of general ICU at Raymond Poincaré University Hospital (APHP) in Garches, France.

He holds high-level strategic positions in France's public health sector and has been involved in several large multinational clinical trials.

Prof. Annane has published more than 300 peer-reviewed articles.
This company-sponsored symposium at Myology 2024 was organised and funded by Alexion, AstraZeneca Rare Disease and intended for Healthcare Professionals. This presentation includes data relating to eculizumab and ravulizumab.
SOLIRIS® (eculizumab) is indicated for the treatment of refractory generalised myasthenia gravis (gMG) in patients aged 6 years and above who are anti-acetylcholine receptor (AChR) antibody-positive.


ULTOMIRIS® (ravulizumab) is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-AChR antibody positive.

Ravulizumab EU Summary of Product Characteristics
Eculizumab EU Summary of Product Characteristics

Prescribing information may differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information. 

Please verify reimbursement status applicable in your country.

Adverse Event Reporting

Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com